DK3654989T3 - Anvendelse af cladribin til behandling af autoimmun neuromuskulær sygdom - Google Patents

Anvendelse af cladribin til behandling af autoimmun neuromuskulær sygdom Download PDF

Info

Publication number
DK3654989T3
DK3654989T3 DK18739593.4T DK18739593T DK3654989T3 DK 3654989 T3 DK3654989 T3 DK 3654989T3 DK 18739593 T DK18739593 T DK 18739593T DK 3654989 T3 DK3654989 T3 DK 3654989T3
Authority
DK
Denmark
Prior art keywords
cladribine
treatment
neuromuscular disease
autoimmune neuromuscular
autoimmune
Prior art date
Application number
DK18739593.4T
Other languages
English (en)
Inventor
Konrad Rejdak
Original Assignee
Chord Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chord Therapeutics Sa filed Critical Chord Therapeutics Sa
Application granted granted Critical
Publication of DK3654989T3 publication Critical patent/DK3654989T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DK18739593.4T 2017-07-21 2018-06-28 Anvendelse af cladribin til behandling af autoimmun neuromuskulær sygdom DK3654989T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease
PCT/GB2018/051801 WO2019016505A1 (en) 2017-07-21 2018-06-28 USE OF CLADRIBINE FOR THE TREATMENT OF AUTOIMMUNE NEUROMUSCULAR DISEASE

Publications (1)

Publication Number Publication Date
DK3654989T3 true DK3654989T3 (da) 2024-02-26

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18739593.4T DK3654989T3 (da) 2017-07-21 2018-06-28 Anvendelse af cladribin til behandling af autoimmun neuromuskulær sygdom

Country Status (13)

Country Link
US (1) US20200163986A1 (da)
EP (2) EP4292663A3 (da)
JP (1) JP7186214B2 (da)
CA (1) CA3095893A1 (da)
DK (1) DK3654989T3 (da)
FI (1) FI3654989T3 (da)
GB (1) GB2564717A (da)
HR (1) HRP20240282T1 (da)
LT (1) LT3654989T (da)
PL (1) PL3654989T3 (da)
PT (1) PT3654989T (da)
RS (1) RS65246B1 (da)
WO (1) WO2019016505A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
WO2001007054A1 (en) * 1999-07-22 2001-02-01 Supergen, Inc. Methods for treating autoimmune diseases
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
AU2003291049A1 (en) * 2002-11-22 2004-06-18 Transclick, Inc. System and method for speech translation using remote devices
ES2584183T3 (es) 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
PL1827461T3 (pl) * 2004-12-22 2012-07-31 Merck Serono Sa Schemat podawania kladrybiny w leczeniu stwardnienia rozsianego
US9925151B2 (en) * 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
EP4292663A3 (en) 2024-03-20
LT3654989T (lt) 2024-03-25
PL3654989T3 (pl) 2024-05-20
EP4292663A2 (en) 2023-12-20
EP3654989A1 (en) 2020-05-27
GB201711800D0 (en) 2017-09-06
JP7186214B2 (ja) 2022-12-08
FI3654989T3 (fi) 2024-03-21
GB2564717A (en) 2019-01-23
WO2019016505A1 (en) 2019-01-24
PT3654989T (pt) 2024-02-28
EP3654989B1 (en) 2024-01-03
HRP20240282T1 (hr) 2024-05-10
JP2020527156A (ja) 2020-09-03
CA3095893A1 (en) 2019-01-24
US20200163986A1 (en) 2020-05-28
RS65246B1 (sr) 2024-03-29

Similar Documents

Publication Publication Date Title
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
HK1209347A1 (en) Use of bacteroides dorei in the treatment or prevention of rheumatoid arthritis or related diseases
HK1209365A1 (en) Use of bacteroides plebeius in the treatment or prevention of rheumatoid arthritis or related diseases
HK1209348A1 (en) Use of bacteroides thetaiotaomicron in the treatment or prevention of rheumatoid arthritis or related diseases
HK1209360A1 (en) Use of bacteroides ovatus in the treatment or prevention of rheumatoid arthritis or related diseases
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
DK3562486T3 (da) Anvendelse af sublingual dexmedetomidin til behandling af agitation
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
IL281274A (en) Methods for treating diuretic resistance
DK3612208T3 (da) Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
PL3202376T3 (pl) Wielofunkcyjna orteza biodra
DK3157522T3 (da) Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste
GB201417163D0 (en) Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
EP3229793A4 (en) Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease
DK3585808T3 (da) Modificerede serpiner til behandlingen af bradykinin formidlet sygdom
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
PT3177599T (pt) Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória
DK3442558T3 (da) Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis
HK1209359A1 (en) Use of megamonas hypermegale in the treatment or prevention of rheumatoid arthritis or related diseases
DK3654989T3 (da) Anvendelse af cladribin til behandling af autoimmun neuromuskulær sygdom
EP3376869A4 (en) AUTOIMMUNE DISEASE TREATMENT